Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: Dr Bernhardt refers to a study that
should have shown that nystatin is effective against esophageal candidiasis,
but this study is an evaluation of 2537 endoscopies and not a randomized trial.1 We showed that the effect of nystatin is similar
to that of placebo in immunocompromised patients. Despite this outcome, the
results for amphotericin B and nystatin had been combined in 3 of the large
trials we identified for our meta-analysis.
Johansen HK, Gøtzsche PC. Improving the Conduct and Reporting of Clinical Trials—Reply. JAMA. 2000;283(21):2787-2790. doi:10.1001/jama.283.21.2787